Best Formulations, a Sirio Pharma Company (Sirio), a nutraceutical contract development and manufacturing organisation (CDMO), has successfully completed its National Sanitation Foundation (NSF) recertification audit.
Aenova, a contract development and manufacturing organisation (CDMO) in the global pharmaceutical supply chain, announces the launch of its Aenovation program.
Bionova Scientific has announced it has licensed ATUM’s proprietary Leap-In Transposase transposon-based gene delivery and its miCHO cell line development technologies.
PCI Pharma Services, a global contract development and manufacturing organisation (CDMO) focused on innovative biopharma therapies, has completed its acquisition of Ajinomoto Althea.
A new, mid-size Contract Development Manufacturing Organisation (CDMO), Meribel Pharma Solutions has launched with an integrated network across Europe, led by a team of industry experts on a mission to deliver the highest quality solutions.
Olivia Friett, editor of European Pharmaceutical Manufacturer was invited to Hillerød, Denmark to see the first expansion of FUJIFILM Diosynth Biotechnologies’ facilities. Olivia spoke to Lars Peterson, president and CEO, about the expansion.
Harvey Branton, senior translational consultant at cell and gene therapy CDMO eXmoor Pharma, shares insights into early process development, exploring common misconceptions that could impact long-term manufacturing success for ATMP developers.
Almac Group has announced the official opening of a new £65m commercial manufacturing facility for Almac Pharma Services at its global headquarters in Craigavon, Northern Ireland.
Adragos Pharma has announced the completion of a €4 million project to install and commission an advanced, cGMP-compliant liquid filling line and accompanying cartoning machine at its facility in Leipzig, Germany.
BioProduction by SEKISUI’s Kirsty Bellchambers and Aurore Laborie-Thompson share insights into what drug developers need to know about transferring their biologics processes to a CDMO partner.
The Indian Contract Research, Development, and Manufacturing Organisation (CRDMO) sector is at an inflection point, with the potential to grow to $22 - $25 billion by 2035, as revealed in a new report, Unleashing the Tiger: Indian CRDMO Sector 2025.
